BR112023015715A2 - Inibidor de cdk - Google Patents

Inibidor de cdk

Info

Publication number
BR112023015715A2
BR112023015715A2 BR112023015715A BR112023015715A BR112023015715A2 BR 112023015715 A2 BR112023015715 A2 BR 112023015715A2 BR 112023015715 A BR112023015715 A BR 112023015715A BR 112023015715 A BR112023015715 A BR 112023015715A BR 112023015715 A2 BR112023015715 A2 BR 112023015715A2
Authority
BR
Brazil
Prior art keywords
compound
cdk inhibitor
preparing
pharmaceutical
cancer
Prior art date
Application number
BR112023015715A
Other languages
English (en)
Inventor
Daqing Sun
Xiaoxia Yan
Original Assignee
Shanghai Qilu Pharmaceutical Res And Development Centre Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Qilu Pharmaceutical Res And Development Centre Ltd filed Critical Shanghai Qilu Pharmaceutical Res And Development Centre Ltd
Publication of BR112023015715A2 publication Critical patent/BR112023015715A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

inibidor de cdk. um composto que serve como um inibidor seletivo de cdk, uma composição farmacêutica contendo o mesmo, um intermediário útil para preparar o composto e um uso do composto para preparar um fármaco para o tratamento de doenças proliferativas celulares, tal como o câncer. o composto tem a estrutura mostrada na fórmula (i-a).
BR112023015715A 2021-02-05 2022-01-28 Inibidor de cdk BR112023015715A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202110161786 2021-02-05
CN202110483256 2021-04-30
CN202111062178 2021-09-10
CN202111398260 2021-11-19
CN202210048365 2022-01-17
PCT/CN2022/074491 WO2022166793A1 (zh) 2021-02-05 2022-01-28 Cdk抑制剂

Publications (1)

Publication Number Publication Date
BR112023015715A2 true BR112023015715A2 (pt) 2023-11-07

Family

ID=82741960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015715A BR112023015715A2 (pt) 2021-02-05 2022-01-28 Inibidor de cdk

Country Status (9)

Country Link
EP (1) EP4289835A1 (pt)
JP (1) JP2024506039A (pt)
KR (1) KR20230142504A (pt)
CN (1) CN116472270A (pt)
AU (1) AU2022215725A1 (pt)
BR (1) BR112023015715A2 (pt)
CA (1) CA3207392A1 (pt)
TW (1) TW202231633A (pt)
WO (1) WO2022166793A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023226920A1 (en) * 2022-05-27 2023-11-30 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors
WO2024027825A1 (zh) * 2022-08-05 2024-02-08 齐鲁制药有限公司 一种cdk抑制剂及其磷酸盐的多晶型

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101044121A (zh) * 2003-02-10 2007-09-26 霍夫曼-拉罗奇有限公司 4－氨基嘧啶－5－酮
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US7423051B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
CN101490041A (zh) * 2006-05-26 2009-07-22 阿斯利康(瑞典)有限公司 作为细胞增殖抑制剂的2-杂环氨基-4-咪唑基嘧啶
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
TW202100520A (zh) * 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
JP2023509260A (ja) * 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
CN115551856A (zh) * 2020-02-28 2022-12-30 重庆复尚源创医药技术有限公司 作为cdk2/4/6抑制剂的化合物

Also Published As

Publication number Publication date
CA3207392A1 (en) 2022-08-11
EP4289835A1 (en) 2023-12-13
TW202231633A (zh) 2022-08-16
CN116472270A (zh) 2023-07-21
JP2024506039A (ja) 2024-02-08
KR20230142504A (ko) 2023-10-11
WO2022166793A1 (zh) 2022-08-11
AU2022215725A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BR112023015715A2 (pt) Inibidor de cdk
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
ECSP109934A (es) Compuesto - 946
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR112103A1 (es) Compuestos para el tratamiento de tnbc
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CL2007001495A1 (es) Compuestos derivados de 4-imidazol-pirimidin-2-amina, inhibidores de la cinasa cdk2;proceso para preparar los compuestos;composicion farmaceutica que comprende a un compuesto;y uso de los compuestos en la preparacion de medicamentos para la proliferacion anticelular,tal como cancer,psoriasis,artritis reumatoide,entre otras.
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
ECSP18056196A (es) Derivados de indano
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
AR126876A1 (es) Inhibidores indolinicos de kif18a